Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial (Q32050572)

5 July 2017

Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial (English)

1 reference

5 July 2017

1 reference

1 reference

A E Tattersfield

1

1 reference

5 July 2017

C G Löfdahl

2

1 reference

5 July 2017

D S Postma

3

1 reference

5 July 2017

A Eivindson

4

1 reference

5 July 2017

A G Schreurs

5

1 reference

5 July 2017

A Rasidakis

6

1 reference

5 July 2017

T Ekström

7

1 reference

5 July 2017

language of work or name

English

0 references

publication date

1 January 2001

1 reference

5 July 2017

1 reference

5 July 2017

357

1 reference

5 July 2017

9252

1 reference

5 July 2017

257-261

1 reference

Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group.

5 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903611-4

7 January 2021

Effect of long-term treatment with salmeterol on asthma control: a double blind, randomised crossover study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903611-4

7 January 2021

Effects of the long acting beta agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. The Netherlands and Canadian Formoterol Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903611-4

7 January 2021

Quality of life in asthma clinical trials: comparison of salmeterol and salbutamol.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903611-4

7 January 2021

Asthma quality of life during 1 year of treatment with budesonide with or without formoterol.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903611-4

7 January 2021

Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903611-4

7 January 2021

Onset and duration of action of single doses of formoterol inhaled via Turbuhaler

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903611-4

7 January 2021

Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903611-4

7 January 2021

Tolerability to high doses of formoterol and terbutaline via Turbuhaler for 3 days in stable asthmatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903611-4

7 January 2021

Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903611-4

7 January 2021

Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903611-4

7 January 2021

Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903611-4

7 January 2021

Formoterol, a new long-acting beta 2 agonist, inhaled twice daily, in stable asthmatic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903611-4

7 January 2021

Formoterol, a new long acting beta 2 agonist for inhalation twice daily, compared with salbutamol in the treatment of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903611-4

7 January 2021

Comparison of the anti-inflammatory properties of formoterol, salbutamol and salmeterol in guinea-pig skin and lung

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903611-4

7 January 2021

Long Duration and High Potency of Antiexudative Effects of Formoterol in Guinea-Pig Tracheobronchial Airways

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903611-4

7 January 2021

Formoterol and salbutamol inhibit bradykinin- and histamine-induced airway microvascular leakage in guinea-pig

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903611-4

7 January 2021

The interaction between salmeterol and beta 2-adrenoceptor agonists with higher efficacy on guinea-pig trachea and human bronchus in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903611-4

7 January 2021

The effects of regular inhaled formoterol, budesonide, and placebo on mucosal inflammation and clinical indices in mild asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903611-4

7 January 2021

Effects of formoterol on histamine induced plasma exudation in induced sputum from normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903611-4

7 January 2021

10.1016/S0140-6736(00)03611-4

Identifiers

DOI

1 reference

5 July 2017

1 reference